HH-120 Nasal Spray for Post-exposure Prevention of SARS-CoV-2
HH-120 Nasal Spray for Post-exposure Prevention of SARS-CoV-2
Enrolling by invitation · NCT05787418 · Registry updated 2024-10-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| HH-120 Nasal Spray for Post-exposure Prevention of SARS-CoV-2 | COVID-19, Coronaviridae Infections, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, RNA Virus Infections, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Enrolling by invitation | Phase 3 | 2024-10-10 | NCT05787418 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Huahui Health | 5 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beijing Ditan Hospital, Capital Medical University | Beijing | China | 1 |
| Huashan Hospital of Fudan University | Shanghai | China | 2 |